[Prognostic significance of Skp2 and p27(kip) in diffuse large B cell lymphoma].
Ritsuko
R
Seki
Koichi
K
Ohshima
Takashi
T
Okamura
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000032:analysis*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D051379:Mice; D008875:Middle Aged; D011379:Prognosis; D000069283:Rituximab; D044786:S-Phase Kinase-Associated Proteins / Q000032:analysis*; D015996:Survival Rate; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C436291:CDKN1B protein, human; D044786:S-Phase Kinase-Associated Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D000069283:Rituximab